MCID: URN010
MIFTS: 59

Urinary Tract Obstruction

Categories: Nephrological diseases

Aliases & Classifications for Urinary Tract Obstruction

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 15 17 72
Obstructive Uropathy 12 55 15
Urinary Obstruction 12
Urologic Diseases 72

Classifications:



External Ids:

Disease Ontology 12 DOID:5200
ICD9CM 35 599.6 599.60
NCIt 50 C3675 C79805
SNOMED-CT 68 7163005
ICD10 33 N13.9
UMLS 72 C0042075 C0178879

Summaries for Urinary Tract Obstruction

MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to obstructive nephropathy and interstitial cystitis, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary Tract Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are HIV Life Cycle and Cytokine Signaling in Immune system. The drugs Alfuzosin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and testes, and related phenotypes are growth/size/body region and immune system

Related Diseases for Urinary Tract Obstruction

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 420)
# Related Disease Score Top Affiliating Genes
1 obstructive nephropathy 31.4 TGFB1 SMAD3 SMAD2 REN EGF ALB
2 interstitial cystitis 31.1 UMOD HBEGF EGF
3 acute cystitis 31.0 KLK3 CCL2 ALB
4 hydronephrosis 30.8 TGFB1 NAGLU EGF CCL2 B2M ALB
5 end stage renal failure 30.8 UMOD TGFB1 FN1 ALB
6 vesicoureteral reflux 1 30.6 UMOD REN NAGLU
7 cystitis 30.5 UMOD PTGS2 HBEGF EGF CCL2
8 pyelonephritis 30.5 UMOD NAGLU CCL2 ALB
9 peritonitis 30.3 CCL2 B2M ALB
10 cystic kidney disease 30.3 UMOD EGF B2M ALB
11 intestinal disease 30.3 PTGS2 PIK3CA ALB
12 adenocarcinoma 30.2 SMAD3 PTGS2 PIK3CA EGF
13 acute kidney tubular necrosis 30.2 UMOD NAGLU B2M ALB
14 interstitial nephritis 30.2 UMOD REN ALB
15 acute kidney failure 30.1 REN EGF B2M ALB
16 clear cell adenocarcinoma 29.8 SMAD3 SMAD2 KLK3
17 autosomal dominant polycystic kidney disease 29.8 REN EGF CCL2 ALB
18 nephrogenic systemic fibrosis 29.7 TGFB1 SMAD3 SMAD2 PIK3CA
19 kidney disease 29.6 UMOD TGFB1 REN NAGLU CCL2 B2M
20 renal fibrosis 29.2 TGFB1 SMAD3 SMAD2 REN CCL2
21 urinary system disease 28.5 UMOD TGFB1 REN NAGLU KLK3 CCL2
22 fetal lower urinary tract obstruction 12.7
23 obsolete: pulmonary aortic stenosis obstructive uropathy 12.4
24 kashani strom utley syndrome 11.9
25 renal hypodysplasia/aplasia 1 11.8
26 potter's syndrome 11.7
27 cystinuria 11.5
28 renal hypodysplasia/aplasia 2 11.5
29 renal hypodysplasia/aplasia 3 11.4
30 small cell carcinoma of the bladder 11.1
31 submandibular gland disease 10.7 TGFB1 KLK3
32 adult hepatocellular carcinoma 10.6 PIK3CA EGF
33 ascending cholangitis 10.6 TGFB1 CCL2 ALB
34 calcifying aponeurotic fibroma 10.5 FN1 EGF
35 lipoid nephrosis 10.5 NAGLU CCL2 ALB
36 tuberculous meningitis 10.5 TGFB1 GGT1 CCL2
37 prostate transitional cell carcinoma 10.5 PIK3CA KLK3
38 oligohydramnios 10.5
39 ureteral obstruction 10.5
40 posterior urethral valves 10.5
41 prostate adenoid cystic carcinoma 10.5 PIK3CA KLK3
42 immunodeficiency 43 10.5 B2M ALB
43 inguinal hernia 10.5
44 retroperitoneal fibrosis 10.4
45 renal dysplasia 10.4
46 leukoregulin 10.4 TGFB1 PTGS2
47 proteasome-associated autoinflammatory syndrome 1 10.4 PTGS2 CCL2 ALB
48 peyronie's disease 10.4 TGFB1 SMAD3 CCL2
49 crohn's disease 10.3
50 membranous nephropathy 10.3 TGFB1 B2M ALB

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 19)


Acute Cystitis Acute Kidney Failure
Bladder Cancer Bladder Neck Obstruction
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Paralytic Ileus
Prostate Calculus Prostate Cancer
Prostatic Hypertrophy Prostatitis
Protein-Energy Malnutrition Ureterolithiasis
Urethral Stricture

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction

Symptoms & Phenotypes for Urinary Tract Obstruction

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, urgency of micturition, other and unspecified genitourinary symptoms, renal colic, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 B2M BNC2 EGF FN1 GGT1 HBEGF
2 immune system MP:0005387 10.35 B2M CCL2 EGF FN1 GGT1 NAGLU
3 homeostasis/metabolism MP:0005376 10.34 ALB B2M FN1 GGT1 HBEGF PIK3CA
4 behavior/neurological MP:0005386 10.32 GGT1 HBEGF NAGLU PIK3CA PTGS2 REN
5 cardiovascular system MP:0005385 10.31 B2M FN1 HBEGF NAGLU PIK3CA PTGS2
6 cellular MP:0005384 10.3 ALB B2M FN1 GGT1 NAGLU PIK3CA
7 mortality/aging MP:0010768 10.28 ALB B2M BNC2 FN1 GGT1 HBEGF
8 endocrine/exocrine gland MP:0005379 10.24 ALB B2M EGF GGT1 PIK3CA PTGS2
9 hematopoietic system MP:0005397 10.21 B2M FN1 GGT1 NAGLU PTGS2 REN
10 digestive/alimentary MP:0005381 10.2 ALB B2M BNC2 EGF PTGS2 SLC5A6
11 integument MP:0010771 10.2 B2M EGF FN1 GGT1 HBEGF NAGLU
12 liver/biliary system MP:0005370 10.09 ALB B2M FN1 NAGLU PTGS2 SLC5A6
13 nervous system MP:0003631 10.06 B2M FN1 HBEGF NAGLU PIK3CA PTGS2
14 neoplasm MP:0002006 9.97 ALB B2M FN1 PIK3CA PTGS2 SMAD2
15 renal/urinary system MP:0005367 9.91 ALB GGT1 NAGLU PTGS2 REN SLC5A6
16 reproductive system MP:0005389 9.85 B2M EGF FN1 GGT1 PIK3CA PTGS2
17 skeleton MP:0005390 9.73 BNC2 FN1 GGT1 HBEGF NAGLU PIK3CA
18 vision/eye MP:0005391 9.23 EGF GGT1 NAGLU PIK3CA PTGS2 SMAD2

Drugs & Therapeutics for Urinary Tract Obstruction

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
2
leucovorin Approved Phase 4 58-05-9 143 6006
3
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
4
Mirabegron Approved Phase 4 223673-61-8 9865528
5
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
10
Povidone Approved Phase 4 9003-39-8
11
Povidone-iodine Approved Phase 4 25655-41-8
12
Iodine Approved, Investigational Phase 4 7553-56-2 807
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
Cimetropium Experimental, Investigational Phase 4 150521-16-7
15
Uric acid Investigational Phase 4 69-93-2 1175
16 Parasympatholytics Phase 4
17 Autonomic Agents Phase 4
18 Vitamins Phase 4
19 Vitamin B9 Phase 4
20 Folate Phase 4
21 Vitamin B Complex Phase 4
22 Mydriatics Phase 4
23 Antiemetics Phase 4
24 Gastrointestinal Agents Phase 4
25 Adjuvants, Anesthesia Phase 4
26 Butylscopolammonium Bromide Phase 4
27 Neurotransmitter Agents Phase 4
28 Adrenergic Agents Phase 4
29 Cholinergic Agents Phase 4
30 Cholinergic Antagonists Phase 4
31 Adrenergic Agonists Phase 4
32 Muscarinic Antagonists Phase 4
33 Adrenergic beta-Agonists Phase 4
34 Adrenergic beta-3 Receptor Agonists Phase 4
35 Solifenacin succinate Phase 4 242478-38-2
36 Anesthetics Phase 4
37 Peripheral Nervous System Agents Phase 4
38 Anticonvulsants Phase 4
39 Bromides Phase 4
40 Anesthetics, Local Phase 4
41 Central Nervous System Depressants Phase 4
42 Antirheumatic Agents Phase 4
43 Neuromuscular Agents Phase 4
44 Neuromuscular Nondepolarizing Agents Phase 4
45 Neuromuscular Blocking Agents Phase 4
46 Antihypertensive Agents Phase 4
47 Angiotensinogen Phase 4
48 Antimalarials Phase 4
49 Angiotensin II Type 1 Receptor Blockers Phase 4
50 Antiparasitic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
2 The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones Unknown status NCT00451061 Phase 4 Alfuzosin;Tamsulosin
3 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
4 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
5 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
6 Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults Completed NCT00301470 Phase 4
7 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
8 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
9 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Recruiting NCT02805504 Phase 4 Exparel;Marcaine
10 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Recruiting NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
11 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Recruiting NCT03591289 Phase 4 NMB with rocuronium bromide
12 A Randomized Trial of Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal to Reduce Bacteriuria and Catheter-Associated Urinary Tract Infections Terminated NCT03447639 Phase 4 Povidone-iodine irrigation
13 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
14 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
15 Assessment of Analgesic Efficacy of Intranasal Desmopressin in the Treatment of Acute Pain in Patients With Renal Colic Unknown status NCT01742689 Phase 3 Desmopressin intranasal spray;Placebo intranasal spray;Indomethacin suppository
16 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3 Omexel;spasfon
17 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
18 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
19 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
20 An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03492281 Phase 3 vibegron;Placebos;Tolterodine Tartrate ER
21 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
22 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
23 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
24 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
25 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
26 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
27 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
28 Saw Palmetto Extract In Benign Prostatic Hyperplasia Completed NCT00037154 Phase 3 Saw Palmetto
29 Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms. A Randomised Controlled Trial Against Standard Therapy Completed NCT00270309 Phase 3
30 A Multicenter, Randomized, Open‐Label, Active‐Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Recruiting NCT03984760 Phase 3 Ferric Citrate;Sevelamer Carbonate
31 An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Active, not recruiting NCT03583372 Phase 3 Vibegron;placebos;Tolterodine Tartrate ER
32 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
33 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Not yet recruiting NCT03927781 Phase 3 Pregabalin 300mg
34 A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
35 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
36 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
37 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
38 Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
39 A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
40 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
41 A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function Completed NCT02118714 Phase 2 Atrasentan
42 RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes) Completed NCT02316821 Phase 2 RTA 402;Placebo
43 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
44 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
45 A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI) Completed NCT01505634 Phase 2 Relebactam 250 mg;Relebactam 125 mg;imipenem/cilastatin 500 mg;Placebo to relebactam;Ciprofloxacin
46 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Recruiting NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
47 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
48 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
49 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Recruiting NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
50 Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2

Search NIH Clinical Center for Urinary Tract Obstruction

Genetic Tests for Urinary Tract Obstruction

Anatomical Context for Urinary Tract Obstruction

MalaCards organs/tissues related to Urinary Tract Obstruction:

41
Kidney, Prostate, Testes, Bone, Brain, Cervix, Neutrophil

Publications for Urinary Tract Obstruction

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 3748)
# Title Authors PMID Year
1
New paradigms for advanced prostate cancer. 9 38
17554403 2007
2
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. 9 38
15017212 2004
3
Glial cell line derived neurotrophic factor is expressed by epithelia of human renal dysplasia. 9 38
12441997 2002
4
[Urinary enzyme excretion in childhood uropathy]. 9 38
12434629 2002
5
[Screening for early detection of prostate cancer (first experience in Israel)]. 9 38
11242898 2001
6
Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. 9 38
10576204 1999
7
Clinical pharmacokinetics and pharmacodynamics of finasteride. 9 38
8846625 1996
8
Tamm-Horsfall protein: are serum levels a marker for urinary tract obstruction? 9 38
7696106 1994
9
[Evaluation of renal function and prediction of renal functional recovery in children with unilateral hydronephrosis using renal pelvic urine]. 9 38
1282579 1992
10
Fetal Cystoscopy and Vesicoamniotic Shunting in Lower Urinary Tract Obstruction: Long-Term Outcome and Current Technical Limitations. 38
31401627 2019
11
Single-use vs reusable digital flexible ureteroscopes for the treatment of renal calculi: a prospective multicenter randomized controlled trial. 38
31432716 2019
12
Diuresis renography in equivocal urinary tract obstruction. A historical perspective. 38
31136948 2019
13
Association between the clinical presentation of congenital anomalies of the kidney and urinary tract (CAKUT) and gene mutations: an analysis of 66 patients at a single institution. 38
30937553 2019
14
Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11-13 weeks' gestation. 38
31408229 2019
15
Congenital urinary tract obstruction. 38
30819578 2019
16
Bilateral obstructive uropathy and micro-bladder after. 38
31274131 2019
17
Laparoscopic Repair of Bochdalek Hernia, Presenting as a Renal Colic. 38
31302134 2019
18
Minimmally invasive resolution of a left ureteral stenosis after Schistosoma haematobium infection. 38
31049287 2019
19
Krt5+ Urothelial Cells are Developmental and Tissue Repair Progenitors in the Kidney. 38
31322419 2019
20
Non-cirrhotic hyperammonemia after deceased donor kidney transplantation: A case report. 38
31347272 2019
21
First-year profile of biomarkers for early detection of renal injury in infants with congenital urinary tract obstruction. 38
30694385 2019
22
Clinical predictors of chronic kidney disease in congenital lower urinary tract obstruction. 38
31197474 2019
23
Comparison of Escherichia coli and Klebsiella pneumoniae Acute Pyelonephritis in Korean Patients. 38
31270992 2019
24
Urethral syringocele: unseen but existing. 38
30836430 2019
25
Myocardial function in fetuses with lower urinary tract obstruction: Is there a cardiac remodeling effect due to renal damage? 38
30957256 2019
26
Epidemiology of and Risk Factors for BK Polyomavirus Replication and Nephropathy in Pediatric Renal Transplant Recipients: An International CERTAIN Registry Study. 38
30130322 2019
27
Fetal megacystis: a lot more than LUTO. 38
30043466 2019
28
Epidemiology and outcomes of acute kidney injury in hospitalized cancer patients in China. 38
30426496 2019
29
Retroperitoneal fibrosis: a rare disease for frontline clinicians. 38
31188341 2019
30
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. 38
30902916 2019
31
Urinary tract infection due to anaerobic bacteria in a two-month-old infant. 38
30686700 2019
32
The role of renal biomarkers to predict the need of surgery in congenital urinary tract obstruction in infants. 38
30979613 2019
33
Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy? 38
31061871 2019
34
Rare Variants in BNC2 Are Implicated in Autosomal-Dominant Congenital Lower Urinary-Tract Obstruction. 38
31051115 2019
35
The protective arm of the renin-angiotensin system may counteract the intense inflammatory process in fetuses with posterior urethral valves. 38
29534877 2019
36
An inventive two-catheter technique to manage an extra-peritoneally ruptured and prolapsed bladder causing obstructive uropathy. 38
31211083 2019
37
In vitro study of age-related changes in human ureteral failure properties according to region, direction, and layer. 38
30922180 2019
38
Urologic care and progression to end-stage kidney disease: a Chronic Kidney Disease in Children (CKiD) nested case-control study. 38
30962011 2019
39
Partial nephrogenic diabetes insipidus associated with Castleman's disease. 38
31088379 2019
40
What predicts spontaneous passage of ≤1 cm ureteral stones in children? 38
31155390 2019
41
Outcome of kidney transplantation from young pediatric donors (aged less than 6 years) to young size-matched recipients. 38
31005637 2019
42
Outcome of fetuses with lower urinary tract obstruction and normal amniotic fluid volume in the second trimester of pregnancy: a single center experience. 38
30977189 2019
43
Antenatal staging of congenital lower urinary tract obstruction. 38
29978555 2019
44
Association between urodynamic parameters and urine neutrophil gelatinase-associated lipocalin concentrations in children with neuropathic bladders. 38
30799170 2019
45
Clinical Profile and Outcome of Children with Congenital Obstructive Uropathy. 38
30796705 2019
46
Protective effects of ghrelin on kidney tissue in rats with partial ureteral obstruction 38
30997983 2019
47
Surgical interventions and anesthesia in the 1st year of life for lower urinary tract obstruction. 38
30049573 2019
48
A classic twin study of lower urinary tract obstruction: Report of 3 cases and literature review. 38
29664229 2019
49
Biometric and morphological features of the fetal bladder in lower urinary tract obstruction on magnetic resonance imaging: new perspectives for fetal cystoscopy. 38
31006924 2019
50
Shortness of Breath: An Unusual Presentation of Bladder Injury. A Case Report and Literature Review of Urinothorax. 38
31281743 2019

Variations for Urinary Tract Obstruction

Expression for Urinary Tract Obstruction

Search GEO for disease gene expression data for Urinary Tract Obstruction.

Pathways for Urinary Tract Obstruction

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 TGFB1 SMAD3 SMAD2 PIK3CA HBEGF FN1
2
Show member pathways
13.26 TGFB1 PTGS2 PIK3CA HBEGF FN1 EGF
3
Show member pathways
12.98 TGFB1 REN PTGS2 HBEGF EGF CCL2
4
Show member pathways
12.9 TGFB1 SMAD3 PTGS2 PIK3CA CCL2 B2M
5
Show member pathways
12.78 TGFB1 SMAD3 SMAD2 PIK3CA KLK3 EGF
6
Show member pathways
12.72 TGFB1 SMAD3 SMAD2 PIK3CA EGF
7 12.65 TGFB1 SMAD3 SMAD2 PTGS2 PIK3CA KLK3
8
Show member pathways
12.54 TGFB1 PIK3CA HBEGF EGF
9 12.31 TGFB1 SMAD3 SMAD2 PIK3CA
10
Show member pathways
12.27 PTGS2 GGT1 CCL2 ALB
11 12.18 TGFB1 SMAD2 PIK3CA HBEGF FN1
12 12.09 TGFB1 SMAD3 SMAD2 PIK3CA
13 12.05 TGFB1 SMAD3 SMAD2 PTGS2 EGF
14 12.04 TGFB1 SLC5A6 HBEGF GGT1
15 11.99 TGFB1 SMAD3 SMAD2 FN1
16
Show member pathways
11.95 TGFB1 SMAD3 SMAD2 PIK3CA EGF CCL2
17
Show member pathways
11.9 TGFB1 SMAD3 SMAD2 PIK3CA EGF
18
Show member pathways
11.9 TGFB1 SMAD3 PIK3CA KLK3 HBEGF EGF
19 11.88 TGFB1 PTGS2 FN1 CCL2
20 11.86 TGFB1 PIK3CA FN1
21 11.84 TGFB1 SMAD3 SMAD2
22 11.82 PTGS2 PIK3CA FN1
23
Show member pathways
11.82 TGFB1 SMAD3 SMAD2
24 11.82 TGFB1 SMAD3 SMAD2
25 11.75 TGFB1 REN PTGS2 CCL2
26
Show member pathways
11.72 TGFB1 SMAD3 SMAD2
27 11.69 TGFB1 SMAD3 SMAD2
28 11.67 TGFB1 PTGS2 CCL2
29
Show member pathways
11.66 TGFB1 SMAD3 SMAD2
30 11.62 TGFB1 SMAD3 EGF
31 11.59 TGFB1 EGF CCL2
32 11.57 KLK3 HBEGF FN1
33 11.49 TGFB1 SMAD3 SMAD2
34 11.48 TGFB1 SMAD3 PTGS2
35 11.47 TGFB1 SMAD3 SMAD2 EGF
36 11.46 TGFB1 PIK3CA FN1
37 11.19 TGFB1 SMAD3 SMAD2
38
Show member pathways
11.12 TGFB1 SMAD3 SMAD2 PIK3CA HBEGF EGF
39 11.1 TGFB1 SMAD3 SMAD2 PIK3CA FN1 CCL2
40 11.08 PIK3CA HBEGF CCL2
41 10.71 TGFB1 SMAD3 SMAD2 FN1

GO Terms for Urinary Tract Obstruction

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 UMOD SLPI NAGLU KLK3 GGT1 FN1
2 extracellular region GO:0005576 9.9 UMOD TGFB1 SLPI REN KLK3 HBEGF
3 endoplasmic reticulum lumen GO:0005788 9.71 PTGS2 FN1 B2M ALB
4 SMAD protein complex GO:0071141 9.37 SMAD3 SMAD2
5 extracellular space GO:0005615 9.36 TGFB1 SLPI REN KLK3 HBEGF GGT1
6 heteromeric SMAD protein complex GO:0071144 9.26 SMAD3 SMAD2
7 platelet alpha granule lumen GO:0031093 9.26 TGFB1 FN1 EGF ALB

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.96 TGFB1 SMAD3 HBEGF EGF
2 MAPK cascade GO:0000165 9.94 TGFB1 HBEGF EGF CCL2
3 cellular protein metabolic process GO:0044267 9.92 KLK3 FN1 B2M ALB
4 cytokine-mediated signaling pathway GO:0019221 9.92 TGFB1 PTGS2 PIK3CA FN1 CCL2
5 positive regulation of protein kinase B signaling GO:0051897 9.89 TGFB1 PIK3CA HBEGF EGF
6 response to lipopolysaccharide GO:0032496 9.88 SLPI REN PTGS2 GGT1
7 transforming growth factor beta receptor signaling pathway GO:0007179 9.85 TGFB1 SMAD3 SMAD2
8 response to organic substance GO:0010033 9.85 TGFB1 REN PTGS2
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 TGFB1 HBEGF EGF
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 TGFB1 PTGS2 PIK3CA
11 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.82 TGFB1 SMAD3 SMAD2
12 platelet degranulation GO:0002576 9.81 TGFB1 FN1 EGF ALB
13 SMAD protein signal transduction GO:0060395 9.78 TGFB1 SMAD3 SMAD2
14 angiogenesis GO:0001525 9.77 PTGS2 PIK3CA FN1 EGF CCL2
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.74 TGFB1 SMAD3 SMAD2
16 ureteric bud development GO:0001657 9.73 TGFB1 SMAD3 SMAD2
17 protein kinase B signaling GO:0043491 9.71 TGFB1 PIK3CA CCL2
18 zymogen activation GO:0031638 9.68 KLK3 GGT1
19 lens fiber cell differentiation GO:0070306 9.67 TGFB1 SMAD3
20 positive regulation of protein import into nucleus GO:0042307 9.67 TGFB1 SMAD3 PTGS2
21 response to cholesterol GO:0070723 9.65 TGFB1 SMAD2
22 primary miRNA processing GO:0031053 9.65 SMAD3 SMAD2
23 nodal signaling pathway GO:0038092 9.65 SMAD3 SMAD2
24 ERBB2 signaling pathway GO:0038128 9.65 PIK3CA HBEGF EGF
25 pericardium development GO:0060039 9.63 SMAD3 SMAD2
26 embryonic foregut morphogenesis GO:0048617 9.63 SMAD3 SMAD2
27 endoderm development GO:0007492 9.63 TGFB1 SMAD3 SMAD2
28 wound healing GO:0042060 9.62 TGFB1 SMAD3 SMAD2 FN1
29 common-partner SMAD protein phosphorylation GO:0007182 9.6 TGFB1 SMAD2
30 positive regulation of extracellular matrix assembly GO:1901203 9.58 TGFB1 SMAD3
31 regulation of striated muscle tissue development GO:0016202 9.55 TGFB1 SMAD3
32 epidermal growth factor receptor signaling pathway GO:0007173 9.46 TGFB1 PIK3CA HBEGF EGF
33 paraxial mesoderm morphogenesis GO:0048340 9.43 SMAD3 SMAD2
34 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.43 TGFB1 SMAD3 SMAD2
35 evasion or tolerance of host defenses by virus GO:0019049 9.4 TGFB1 SMAD3
36 SMAD protein complex assembly GO:0007183 9.13 TGFB1 SMAD3 SMAD2
37 regulation of binding GO:0051098 8.8 TGFB1 SMAD3 SMAD2
38 positive regulation of cell proliferation GO:0008284 10.07 TGFB1 PTGS2 HBEGF FN1 EGF
39 negative regulation of cell proliferation GO:0008285 10.02 UMOD TGFB1 SMAD3 SMAD2 PTGS2
40 positive regulation of gene expression GO:0010628 10.01 TGFB1 SMAD3 SMAD2 FN1 EGF

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.55 TGFB1 SMAD3 SLPI PTGS2 FN1
2 enhancer binding GO:0035326 9.43 SMAD3 SMAD2
3 type I transforming growth factor beta receptor binding GO:0034713 9.4 TGFB1 SMAD2
4 co-SMAD binding GO:0070410 9.37 SMAD3 SMAD2
5 primary miRNA binding GO:0070878 9.26 SMAD3 SMAD2
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.02 PIK3CA
7 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 8.96 SMAD3 SMAD2
8 transforming growth factor beta receptor binding GO:0005160 8.8 TGFB1 SMAD3 SMAD2

Sources for Urinary Tract Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....